Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Remission indicates symptom disappearance, not a cure, especially in chronic diseases like follicular lymphoma. Blood cancers are challenging to eradicate due to their systemic nature, requiring ...

One of the most difficult issues to deal with as a cancer survivor is the positivity trap. Four and a half years ago, I was diagnosed with follicular lymphoma, a form of blood cancer that is ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

FL with blastoid or large centrocyte cytologic features, or follicular large B-cell lymphoma (FL grade 3B) are excluded. Rituximab/hyaluronidase human is administered subcutaneously (first dose IV ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.